These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 32946819)

  • 1. Draft FDA guidance for assessing the safety of glucose lowering therapies: a missed opportunity?
    Khunti K; Davies MJ; Marx N; Buse JB
    Lancet Diabetes Endocrinol; 2020 Oct; 8(10):810-811. PubMed ID: 32946819
    [No Abstract]   [Full Text] [Related]  

  • 2. Glycemic management in diabetes and the associated cardiovascular risk: are we helping or hurting our patients?
    Koshizaka M; Green JB; Alexander JH
    Circ J; 2012; 76(7):1572-80. PubMed ID: 22789974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycemic control and cardiovascular mortality.
    Riddle MC
    Curr Opin Endocrinol Diabetes Obes; 2011 Apr; 18(2):104-9. PubMed ID: 21522000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of cardiovascular outcomes on the development and approval of medications for the treatment of diabetes mellitus.
    Joffe HV; Parks MH; Temple R
    Rev Endocr Metab Disord; 2010 Mar; 11(1):21-30. PubMed ID: 20195772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions.
    Sharma A; Pagidipati NJ; Califf RM; McGuire DK; Green JB; Demets D; George JT; Gerstein HC; Hobbs T; Holman RR; Lawson FC; Leiter LA; Pfeffer MA; Reusch J; Riesmeyer JS; Roe MT; Rosenberg Y; Temple R; Wiviott S; McMurray J; Granger C
    Circulation; 2020 Mar; 141(10):843-862. PubMed ID: 31992065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [112th Scientific Meeting of the Japanese Society of Internal Medicine: Symposium: Emerging Comorbidities of Diabetes Mellitus: Drug Therapy of Diabetes Mellitus to Prevent Complications].
    Inagaki N
    Nihon Naika Gakkai Zasshi; 2015 Sep; 104(9):1912-6. PubMed ID: 30160897
    [No Abstract]   [Full Text] [Related]  

  • 7. Geographic Variation in Rosiglitazone Use Surrounding FDA Warnings in the Department of Veterans Affairs.
    Ahuja V; Sohn MW; Birge JR; Syverson C; Budiman-Mak E; Emanuele N; Cooper JM; Huang ES
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1214-34. PubMed ID: 26679970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategies for the development of new PPAR agonists in diabetes.
    Cavender MA; Nicholls SJ; Lincoff AM
    Eur J Cardiovasc Prev Rehabil; 2010 May; 17 Suppl 1():S32-7. PubMed ID: 20489419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDA guidance on antihyperglyacemic therapies for type 2 diabetes: One decade later.
    McGuire DK; Marx N; Johansen OE; Inzucchi SE; Rosenstock J; George JT
    Diabetes Obes Metab; 2019 May; 21(5):1073-1078. PubMed ID: 30690856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of FDA guidance for developing diabetes drugs on trial design: from policy to practice.
    Bethel MA; Sourij H
    Curr Cardiol Rep; 2012 Feb; 14(1):59-69. PubMed ID: 22094711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Anti-diabetic therapy and cardiovascular disease].
    Mannucci E
    G Ital Cardiol (Rome); 2016 Mar; 17(3 Suppl 2):3s-4. PubMed ID: 27030117
    [No Abstract]   [Full Text] [Related]  

  • 12. FDA upholds findings of UGDP study.
    JAMA; 1979 Jan; 241(1):17-8. PubMed ID: 758481
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of diabetic complications: how can we learn by seeking and blundering?
    Pafili K; Papanas N; Maltezos E
    Angiology; 2015 Apr; 66(4):301-3. PubMed ID: 25092682
    [No Abstract]   [Full Text] [Related]  

  • 14. Cardiologists and the management of blood sugar: a Chinese perspective.
    Hu DY; Guo YF
    Nat Clin Pract Cardiovasc Med; 2008 Sep; 5(9):509. PubMed ID: 18719711
    [No Abstract]   [Full Text] [Related]  

  • 15. Diabetes management: More than just cardiovascular risk?
    Zimmerman RS; Pantalone KM
    Cleve Clin J Med; 2014 Nov; 81(11):672-6. PubMed ID: 25368217
    [No Abstract]   [Full Text] [Related]  

  • 16. Cardiovascular safety and diabetes drug development.
    Drucker DJ; Goldfine AB
    Lancet; 2011 Mar; 377(9770):977-9. PubMed ID: 21316097
    [No Abstract]   [Full Text] [Related]  

  • 17. Cardiovascular outcome trials of diabetes drugs: lessons learned.
    Taylor SI; Leslie BR
    J Clin Invest; 2018 Mar; 128(3):893-896. PubMed ID: 29431733
    [No Abstract]   [Full Text] [Related]  

  • 18. Assessing the Safety of Glucose-Lowering Drugs - A New Focus for the FDA.
    Chong WH; Yanoff LB; Andraca-Carrera E; Thanh Hai M
    N Engl J Med; 2020 Sep; 383(13):1199-1202. PubMed ID: 32966719
    [No Abstract]   [Full Text] [Related]  

  • 19. [Cardiovascular outcome trials in patients with diabetes].
    Mannucci E
    G Ital Cardiol (Rome); 2014 Dec; 15(12 Suppl 2):27S-31S. PubMed ID: 25623548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA approach to the regulation of drugs for diabetes.
    Fleming A
    Am Heart J; 1999 Nov; 138(5 Pt 1):S338-45. PubMed ID: 10539795
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.